Attention www.globalkeysolutions.net is now www.keypedia.com, read the full press release here.
KeyPedia LogoKeyPedia Icon
  1. Home
  2. /
  3. Records
  4. /
  5. Eir
  6. /
  7. Halo Pharmaceutical, Inc. d/b/a Cambrex Whippany
EIR
•Halo Pharmaceutical, Inc. d/b/a Cambrex Whippany•December 20, 2019

Halo Pharmaceutical, Inc. d/b/a Cambrex Whippany – FDA EIR, Dec 20, 2019

Record Details

An FDA inspection of Halo Pharmaceutical, Inc., also operating as Cambrex Whippany, was conducted from December 9 to December 20, 2019. This comprehensive GMP and pre-approval inspection covered quality, laboratory control, production, and material systems, including coverage for ANDA 213438, Hydroxyurea Capsules USP 500mg. The inspection resulted in an FDA Form 483, detailing significant observations. Main violations included the failure to follow procedures for warehousing drug products, specifically regarding the proper control, accountability, and storage or destruction of materials under investigation. Furthermore, the quality control unit did not fully adhere to its written responsibilities and procedures, with numerous investigations failing to close within the mandated 30-day timeframe or without proper extension documentation, violating 21 CFR 211.22(d). Additional issues identified involved deficiencies in data integrity, such as unintegrated or unevaluated unknown peaks in HPLC data for product testing, and an inadequate, non-procedure-driven audit trail review process for laboratory software. The firm also deviated from stability protocols without initiating proper deviation reports and exhibited inconsistent product handling practices, including operators touching drug products with bare skin or gloved hands without proper glove changes, and wearing jewelry in GMP areas. Equipment cleaning procedures were found to be insufficient, and a planned deviation for a sterile filling line was not fully documented or consistently followed. Halo Pharmaceutical management acknowledged the findings and committed to submitting a written response to the FDA 483 observations within 15 business days, with some immediate actions indicated for specific issues.

Company
Halo Pharmaceutical, Inc. d/b/a Cambrex Whippany
Inspection date
December 20, 2019
Product type
drugs
Office
New Jersey District Office
People
  • Niketa Patel (Consumer Safety Officer/ORA/OMPTO/TOS)
  • Emmanuel J. Ramos (Compliance Officer at FDA)
View Company Profile

ID · 811b1d79-833d-4528-bf63-382c0e77803e

Violation Codes1
21 CFR 211.22(d)

Full citation text and observation details available on the Dashboard.

Other documents for Halo Pharmaceutical, Inc. d/b/a Cambrex Whippany
  • 483 - 2023-02-17February 17, 2023
  • 483 - 2019-12-20December 20, 2019
  • EIR - 2017-03-20March 20, 2017
  • 483 - 2017-03-20March 20, 2017

Your cart

Your cart is empty.

Browse public document pages and click Buy this document. We'll ask for your email at checkout, no account needed up front.

Browse documents

Discuss this record with AI

KeyPedia

ChatGPT

Claude

Perplexity

Grok

Copilot

Document or profile

One record shows the event. A profile shows the pattern.

Buy this document for the source file and details behind this single event.

Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.

Explore Halo Pharmaceutical, Inc. d/b/a Cambrex Whippany
KeyPedia
Regulatory Data Transformed
Stay in the loop

KRA score changes, company updates and news. About monthly, unsubscribe anytime.

Contact
New York Office:
370 Jay Street 7th Floor
Brooklyn, NY 11201
Scranton Office:
Scranton Enterprise Center, Suite 217
201 Lackawanna Avenue
Scranton, PA, 18503
🇺🇸+1 917-789-5099
🇪🇺+48 532-447-507
info@keypedia.com
Quick Links
HomePlatform OverviewMedia
KeyPedia™ Lite
Browse HubDatabase DirectoryRecordsCompaniesOfficesPeopleCareersAbout UsFounding TeamMeet Our ExpertsPartners
Legal & Ethics
Privacy PolicyTerms of ServiceOur Values & MissionCode of Ethics & AI Policy
©2026 KeyPedia™ | Global Key Solutions Corp. All rights reserved.